Skip to main content
Everything PR News
Company Profiles

Merck & Co.: Keytruda, CEO, Sales and the 2028 Patent Cliff

EPR Editorial Team5 min read
Share
Merck & Co.: Keytruda, the 2028 Patent Cliff, and the Post-Cliff Pipeline

Merck & Co. (NYSE: MRK) is the Rahway, New Jersey pharmaceutical company behind Keytruda, the cancer drug with the highest sales in its portfolio. Merck reported full-year 2025 worldwide sales of $65.0 billion, of which Keytruda and its subcutaneous version Keytruda Qlex made up $31.7 billion, according to Merck's February 3, 2026 results release. Robert M. Davis is chairman and chief executive officer, and the company operates as MSD outside the United States and Canada.

Part of EPR's Pharma pillar and Healthcare pillar. This is the Merck & Co. coverage hub on Everything-PR. By the EPR Editorial Team, updated October 2026. This page describes a company and its communications, and it is not medical advice.

What are the key facts about Merck & Co.?

FactDetail
Founded1891, as the U.S. arm of the German company E. Merck
HeadquartersRahway, New Jersey
TickerNYSE: MRK
Chairman and CEORobert M. Davis, CEO since July 2021
2025 worldwide sales$65.0 billion (1% growth), per Merck
2025 Keytruda and Keytruda Qlex sales$31.7 billion (7% growth), per Merck
2025 Animal Health sales$6.4 billion (8% growth), per Merck

Merck & Co. and the German company Merck KGaA are two separate companies. Merck & Co. began as the U.S. subsidiary of E. Merck and became independent after World War I, when U.S. assets of German-owned companies were seized and sold.

What is Keytruda, and why does it matter to Merck?

Keytruda (pembrolizumab) is a PD-1 immune checkpoint inhibitor first approved by the FDA in September 2014 for advanced melanoma. Merck's filings say it is now approved in the U.S. in over 45 indications across 19 tumor types and two tumor-agnostic indications. It made up roughly half of Merck's 2025 sales, which is why the company's strategy centers on what comes after it.

Keytruda Qlex, a subcutaneous version of Keytruda combined with berahyaluronidase alfa, was first approved by the FDA in September 2025 for solid tumor indications approved for Keytruda, and the European Commission approved a subcutaneous version in November 2025. Merck also discloses litigation with Halozyme about the technology.

What is the Keytruda patent cliff?

The Keytruda patent cliff is the expected loss of U.S. market exclusivity for the drug in 2028, as widely reported, after which biosimilar competition is expected to reduce its revenue. Merck's response has three parts: subcutaneous formulations, expanded indications, and acquisitions. EPR describes the cliff as the largest single revenue-replacement challenge in the industry, which is EPR's characterization.

How is Merck replacing Keytruda revenue?

Merck is buying and licensing new products. The table lists the deals EPR has verified against Merck's disclosures.

DealDateWhat it added
Acceleron PharmaNovember 2021Sotatercept, approved as Winrevair for pulmonary arterial hypertension in March 2024
Prometheus BiosciencesJune 2023A TL1A-targeting drug for inflammatory bowel disease
Daiichi Sankyo collaborationOctober 2023Three antibody-drug conjugates in oncology
Verona PharmaClosed October 2025Ohtuvayre, a maintenance treatment for COPD, in an acquisition of about $10 billion
Cidara TherapeuticsClosed January 2026A long-acting antiviral designed to prevent influenza

Winrevair sales were $1.4 billion in 2025, per Merck's results release.

What other products does Merck sell?

Merck's other major products include the HPV vaccine Gardasil and Gardasil 9, which had $5.2 billion in 2025 sales, a 39% decline, per Merck. It also sells Bridion for reversing neuromuscular blockade during surgery, Welireg for certain kidney cancers, and Lagevrio, an oral COVID-19 antiviral that received an FDA emergency use authorization in December 2021. Merck Animal Health sells veterinary medicines and vaccines, including Bravecto and Nobivac. Merck spun off its women's health and biosimilars business as Organon in June 2021.

How does Merck handle communications?

Merck's communications work centers on three recurring tasks. It supports Keytruda across dozens of cancer indications through trade press and scientific affairs. It explains the post-Keytruda strategy to investors. And it manages pricing policy, including the Inflation Reduction Act, under which Januvia was among the first drugs selected for Medicare price negotiation. EPR's observation is that CEO Davis has a lower public profile than some peers, and that Merck leans on scientific affairs and trade press over consumer-facing CEO visibility.

How does Merck rank in AI answers?

In EPR's Pharma AI Citation Share Study, Merck ranks fifth among large pharma companies despite owning a top-selling drug, and EPR concludes that advertising spend does not predict AI citation share. These are EPR's own study results. See also Pharma Spent $8 Billion on TV. The Chatbox Cited Eli Lilly Anyway.

TagsPharma

Frequently Asked Questions

When was Merck & Co. founded?

Merck & Co. was established in 1891 as the U.S. subsidiary of the German company E. Merck and became independent after World War I.

Is Merck & Co. the same as Merck KGaA?

No. They are two separate companies, and Merck & Co. operates as MSD outside the United States and Canada to avoid confusion.

Who is the CEO of Merck & Co.?

Robert M. Davis is chairman and chief executive officer. He became CEO in July 2021, succeeding Kenneth Frazier, and was previously the company's chief financial officer.

What are Keytruda's 2025 sales?

Keytruda and Keytruda Qlex had $31.7 billion in 2025 sales, a 7% increase, according to Merck's February 2026 results.

When does Keytruda lose patent protection?

U.S. exclusivity is widely expected to end in 2028, after which biosimilar competition is expected. Merck is responding with subcutaneous formulations, new indications, and acquisitions.

What did Merck acquire in 2025?

Merck closed its acquisition of Verona Pharma, which brought it Ohtuvayre for COPD, in October 2025, and agreed to acquire Cidara Therapeutics, which closed in January 2026. The decision for a pharma communications team is to publish current, sourced facts about its post-patent pipeline before the cliff arrives, since AI answers will otherwise rely on older coverage. Related: Pharma pillar, Healthcare pillar, Pharma AI Citation Share Study, and UnitedHealth 2024 Crisis. Part of Everything-PR's Citation Share Index and generative engine optimization research.

EPR Editorial Team
Written by
EPR Editorial Team

The Everything-PR Editorial Team is the staff byline for news, analysis and features on public relations, crisis communications, reputation, AI visibility and digital discovery. Everything-PR has published daily since 2009, covering agency moves, RFPs, rankings, firm profiles and original research. Every article is reviewed by a human editor before publication. Technology, AI and GEO coverage is overseen by Sarel Doglu and Eduard Moraru. Coverage follows the Editorial Policy, and substantive corrections are noted on the article under the Corrections Policy.

Related reading

Other news

See all

Most brands are invisible inside AI search. Is yours?

EPR publishes the data every week.

Free. Weekly. Unsubscribe anytime.